Evidence map›Paper›PMID 41438589›Full record

ArticleJournal of pathology informatics2025

Quantifying partial pathological response rate in prostate cancer patients who underwent neoadjuvant chemotherapy using a novel morphometric approach.

Wei Huang, Huihua Li, Philipos Tsourkas, Sean Mcilwain, Irene Ong, Christos E Kyriakopoulos, Brian Johnson, Steve Y Cho, Shane A Wells, Alejandro Roldan Alzate and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pathology informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Wei HuangDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.
Huihua LiDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.
Philipos TsourkasBiostatistics and Medical Informatics, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.
Sean McilwainBiostatistics and Medical Informatics, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.
Irene OngBiostatistics and Medical Informatics, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.
Christos E KyriakopoulosDepartment of Medicine, Hematology/Oncology Division, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.
Brian JohnsonDepartment of Pharmacology and Toxicology, Michigan State University, East Lansing, MI, USA.
Steve Y ChoDepartment of Radiology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.
Shane A WellsDepartment of Radiology, University of Michigan, East Lansing, MI, USA.
Alejandro Roldan AlzateMechanical Engineering, College of Engineering, University of Wisconsin-Madison, Madison, WI, USA.
David F JarrardDepartment of Urology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.
Erika HeningerDepartment of Medicine, Hematology/Oncology Division, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.
Joshua M LangDepartment of Medicine, Hematology/Oncology Division, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate assessment of partial pathological response rate (ppRR) to neoadjuvant chemotherapy (NAT) is critical for assessing the efficacy of therapy and for optimal clinical management. Because of a lack of accurate estimation of baseline cancer burden, assessment of ppRR has never been attempted in prostate histologically. We presented a novel morphometric approach assessing ppRR in patients who underwent NAT and then correlated the ppRR with patients' outcomes. A control cohort consisted of 39 NAT-naïve Caucasian patients who had high-risk PCa (defined as Gleason Grade Group >2) and an adequate biopsy sample (defined as the size of the biopsy PCa area, including PCa epithelium and stroma >2

Indexed as

Epithelial to stromal ratio (E/S)NATOutcomePartial pathological response rate (ppRR)PCa

Identifiers

PMID41438589
PMCPMC12721136

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.